Pds biotech announces agreement with university of georgia to license novel proteins for versamune-based universal flu vaccine

Florham park, n.j., nov. 01, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® t-cell activating technology, today announced an agreement to license cobra (computationally optimized broadly reactive antigen) antigens from the university of georgia initially for use in the clinical development of its infectious disease immunotherapy pipeline, pds0202, a universal flu vaccine candidate.
PDSB Ratings Summary
PDSB Quant Ranking